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Advanced glycation endproducts (AGEs) and a receptor for
AGEs (RAGE) have been linked in the pathogenesis of
diabetic nephropathy. RAGE is usually localized to podocytes
and is increased in diabetes. RAGE activation increases
reactive oxygen species production, which mediates
hyperglycemia-induced podocyte apoptosis in early diabetic
nephropathy. Here, we examined the interaction of AGE and
RAGE on podocyte apoptosis. When we exposed murine
cultured podocytes to bovine serum albumin (BSA) that was
modified by AGEs or to carboxymethyl-lysine BSA, more
apoptosis was found when compared with unmodified BSA.
Similarly, more podocytes underwent detachment and
apoptosis when cultured on AGE-modified collagen IV than
on native collagen IV. AGEs isolated from sera of patients
with chronic kidney disease also caused apoptosis of
podocytes. Apoptosis was diminished by small interference
RNA (siRNA) for RAGE in podocytes exposed to AGE-BSA, but
not to AGE-modified collagen IV. Both AGE- and
carboxymethyl-lysine modified-BSA activated p38MAP kinase
and inhibition of this kinase reduced the apoptotic effect of
AGE-BSA. Exposure to AGE-BSA was associated with Akt
dephosphorylation and FOXO4 transcriptional activation
leading to an increase in the expression of an effector protein
of apoptosis, Bim. siRNA for FOXO4 abolished AGE-BSA-
induced apoptosis of podocytes. Our study suggests that
an AGE–RAGE interaction contributes to podocyte apoptosis
by activation of the FOXO4 transcription factor.
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Diabetic nephropathy is the major cause of chronic and end-
stage renal disease in the United States.1 None of the
currently available pharmacologic interventions for diabetic
nephropathy can completely forestall or reverse the progres-
sion of the disease. Much is known of the progression of
glomerulosclerosis and tubulointerstitial fibrosis in diabetic
nephropathy after the onset of albuminuria as mediated by
TGF-b, angiotensin II, and advanced glycation endproducts
(AGEs).2,3 However, cellular events preceding the onset of
albuminuria in diabetic nephropathy have not been well
characterized.
The podocyte is a terminally differentiated cell with a
limited capacity to proliferate and regenerate after injury.
Any disease process that causes podocyte loss, either from
detachment or apoptosis, will lead to a decrease in the
density of podocytes. Reduction in podocyte density is an
important determinant of progressive diabetic nephropathy4
and precedes the development of renal dysfunction and
albuminuria in diabetic patients and animal models of
diabetes mellitus.4–6 There is a body of emerging literature,
suggesting that podocyte loss is an early finding in diabetic
nephropathy.7 A recent study by Susztak et al. showed that
hyperglycemia causes podocyte apoptosis through a reactive
oxygen species (ROS)-mediated pathway during the early
stage of diabetic nephropathy.6 Our knowledge of the
extracellular signals and intracellular responses leading to
podocyte apoptosis in the diabetic milieu, however, remains
limited.
One of the changes that occur as a result of elevated blood
glucose in diabetes mellitus is the generation and accumula-
tion of AGEs. Both AGEs and their receptors have been
shown to play a key role in the pathogenesis of diabetic
nephropathy.3,8–12 The receptor for AGEs (RAGE) is a
member of the immunoglobulin superfamily of cell surface
molecules.13 Ligand binding to RAGE by AGEs or members
of the S100/calgranulin family triggers the activation of key
cell signaling pathways, such as p21ras, mitogen-activated
protein kinases (MAPKs), and nuclear factor-kB (NF-kB),
leading to the activation of proinflammatory responses.14–16
The expression of RAGE is localized predominately to the
podocyte and further increased in diabetes.3 Wautier et al.17
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showed that AGEs initiate a vicious cycle of inflammation
involving the generation of ROS via the activation of NADPH
oxidase with further amplification of AGE production and
inflammatory reaction. This observation was corroborated by
our recent study showing that AGEs enhance ROS produc-
tion.18
In diabetes, the extracellular matrix of the glomerular
basement is modified by AGEs. The accumulation of AGEs
and subsequent expansion of the glomerular basement
membrane occur before the onset of albuminuria in the
early phase of diabetic nephropathy.19 Podocytes cover the
glomerular basement membrane and constitute an integral
component of the glomerular filtration barrier. They are
exposed to both circulating and glomerular-basement-
membrane-bound AGEs. In this study, we tested the
hypothesis that soluble and matrix-bound AGEs contribute
to podocyte apoptosis via the activation of the AGE–RAGE
axis, the FOXO4 transcription factor, and ROS production.
RESULTS
AGE exposure causes podocyte apoptosis
We examined the effects of soluble AGEs (CML-bovine
serum albumin (BSA) and AGE-BSA) and matrix-bound
AGEs (AGE-modified collagen IV) on podocyte apoptosis.
Podocytes exposed to either Carboxymethyl-lysine-BSA
(CML-BSA) or AGE-BSA underwent apoptosis at signifi-
cantly higher rates than BSA (Figure 1). There was a two- to
threefold increase in apoptosis when podocytes were cultured
on AGE-modified collagen IV as compared with native
collagen IV (Figure 1c). A similar increase in apoptosis was
also noted when podocytes were cultured on AGE-modified
collagen I as compared with native collagen I (data not
shown). Effects of soluble (CML-BSA and AGE-BSA) and
matrix-bound (AGE-modified collagen IV) AGEs on apop-
tosis were additive (Figure 1c). The apoptotic response of
podocytes to AGE-BSA exposure occurred in a dose-
dependent manner (Figure 2). Significant podocyte necrosis
occurred at 100 mg/ml of AGE-BSA (Figure 2).
Effect of soluble and matrix-bound AGEs on podocyte
detachment, apoptosis, and necrosis
To investigate podocyte detachment, apoptosis, and necrosis
after exposure to soluble and matrix-bound AGEs, we treated
podocytes cultured on plates coated with either collagen IV or
AGE-modified collagen IV with AGE-BSA. The absolute
number and percentage of cells in each group were
determined and presented as means7s.e.m. (n¼ 3). Statis-
tical analyses were performed on the percentages of cells
relative to the total number of cells. Although the total cell
number and total adherent cell number did not differ
between all conditions, a higher proportion of podocytes
cultured on AGE-modified collagen IV became detached as
compared with collagen IV (Table 1). All the detached cells
were non-viable by Trypan blue staining. Exposure to in-
creasing doses of AGE-BSA did not cause a significant change
in the percentages of detached cells for both collagen-IV-
and AGE-modified collagen-IV-coated plates. However, there
was a dose response increase in the apoptosis of adherent
cells with AGE-BSA treatment.
The role of RAGE in AGE-BSA-induced podocyte apoptosis
To determine the role of RAGE in AGE-BSA-induced
podocyte apoptosis, we knocked down RAGE expression by
transfecting podocytes with a RAGE-specific small inter-
ference RNA (siRNA). The efficiency of transfection was
demonstrated by concurrent transfection with a green
fluorescent protein (GFP)-vector (Figure 3a). The siRNA
was able to reduce the RAGE mRNA level and protein
expression by 60–70% (Figure 3b and c). We found that
podocytes transfected with the RAGE-specific siRNA had a
significantly diminished apoptosis when exposed to 10 and
50 mg/ml of AGE-BSA, but only partially when exposed to
100 mg/ml (Figure 4a). RAGE-specific gene knockdown did
not significantly reduce the apoptosis of podocytes cultured
on AGE-modified collagen IV (Figure 4b), although a trend
towards a reduction was observed. These results suggest that
the AGE–RAGE interaction played a major role in the
apoptosis of podocytes triggered by soluble AGE, but not by
matrix-bound AGE.
AGEs isolated from patients with renal impairment caused
podocyte apoptosis in vitro
Patients with chronic kidney disease (CKD) have higher
serum levels of AGEs. To ensure that the apoptosis we
observed in podocytes exposed to AGE-BSA and CML-BSA
was not an artifact of the in vitro AGE preparation process,
we isolated AGEs from sera of patients with CKD. The
concentration of AGEs from patients with CKD was 46-fold
higher than patients without CKD (55 versus 1.2 U/mg
protein as measured by enzyme-linked immunosorbent
assay). AGEs isolated from patients with stages 3 and 5
CKD caused a three and 4.6-fold increase in podocyte
apoptosis, respectively, as compared with those from normal
patients (Figure 5). We were able to abrogate the apoptotic
effect of AGEs isolated from patients with CKD by
pretreating the cultured podocytes with the siRNA for RAGE
(Figure 5). These results suggest that the serum fraction
extracted by a lysozyme (LZ) column caused the apoptosis of
cultured podocytes via a pathway involving RAGE. Although
we cannot exclude other co-extracted proteins contributing
to the apoptosis of podocytes, it appears likely that AGE-like
structures are the cause.
AGE-BSA triggers ROS production leading to podocyte
apoptosis
AGE–RAGE interaction leading to an increase in ROS
production has been shown to cause apoptosis of fibroblasts
and neuronal cells.20,21 To test whether ROS production is
triggered by AGE–RAGE interaction in podocytes, we
transfected podocytes with a RAGE-specific siRNA and
measured the production of ROS after AGE-BSA stimulation.
There was a dose-dependent increase in ROS production
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with AGE-BSA exposure, which was diminished in podocytes
transfected with the siRNA for RAGE (Figure 6a). To verify
that ROS production by AGE-BSA stimulation was respon-
sible for podocyte apoptosis, we incubated podocytes with a
ROS scavenger, N-acetyl-cysteine (NAC). Treatment with
NAC reduced AGE-BSA-induced apoptosis (Figure 6b and c).
Activation of proapoptotic intracellular signaling pathways
by AGEs
Using Panomics TranSignal DNA/protein arrays as an
approach to profile multiple transcription factors simulta-
neously, we identified FOXO4 as the only transcription factor
from the forkhead family that was activated by AGE-BSA and
CML-BSA stimulation. To determine the regulation of
FOXO4 by upstream signaling pathways after AGE exposure,
we performed Western blotting of proteins prepared from
podocytes stimulated with BSA, CML-BSA, or AGE-BSA
(Figure 7). The Akt signaling pathway is a known upstream
regulator of FOXO4 transcription factors. Akt-mediated
phosphorylation of FOXO4 promotes nuclear exclusion and
transcriptional deactivation.22 Immunoblotting results
showed that both CML-BSA and AGE-BSA diminished
phosphorylation of Akt without a significant change of
phosphatas and tensin homologue levels (Figure 7a). After
60 min of incubation with AGE-BSA and CML-BSA, the level
of phosphorylated FOXO4 was decreased, likely due to a
diminished Akt activity (Figure 7a). Dephosphorylation of
FOXO4 is known to cause transcriptional activation of
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Figure 1 | Podocyte apoptosis with soluble (CML-BSA and AGE-BSA) and matrix-bound AGE (AGE-modified collagen IV) exposures.
Differentiated podocytes cultured on coverslips coated with either collagen IV or AGE-modified collagen IV were exposed to 50 mg/ml of BSA,
AGE-BSA, or CML-BSA for overnight. Apoptosis of podocytes was determined by TUNEL staining. (a, b) Representative photographs of TUNEL
staining are presented. (c) Bar graph representing the means7s.e.m. of the number of apoptotic nuclei per 100 cells in five fields at original
magnification 400. *Po0.01 as compared with BSA exposure on collagen-IV-coated coverslips (n¼ 4). **Po0.01 as compared with
corresponding collagen-IV-coated coverslips (n¼ 4).
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FOXO4, which is consistent with our observation from the
Panomics TranSignal DNA/protein arrays.
Hyperglycemia and puromycin have been reported to
cause podocyte apoptosis through activation of the p38MAP
kinase (p38MAPK) pathway.6,23 We found that both AGE-
BSA and CML-BSA caused a transient activation of
extracellular signal-regulated kinase1/2 at 10 min and a more
sustained activation of p38MAPK from 30 min to 2 h after
AGE-BSA and CML-BSA stimulations (Figure 7a). c-Jun
NH2-terminal kinase (JNK) phosphorylation with or with-
out AGE-BSA and CML-BSA stimulation was too weak for
detection (data not shown). Targeted gene knock down of
RAGE in podocytes prevented AGE-BSA-induced Akt dephos-
phorylation and p38MAPK phosphorylation (Figure 7b). To
confirm that p38MAPK contributes to AGE-BSA-mediated
podocyte apoptosis, we inhibited p38MAPK in podocytes
before AGE-BSA exposure. AGE-BSA-induced podocyte
apoptosis was partially diminished by inhibition of
p38MAPK with a specific inhibitor (Figure 8).
Role of transcription factor FOXO4 in AGE-induced podocyte
apoptosis
It is known that dephosphorylation of FOXO transcription
factors leads to nuclear translocation and activation of gene
transcription. To further confirm our Panomics TranSignal
DNA/protein array and Western blot result on FOXO4
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Figure 2 | Podocytes undergo apoptosis after AGE-BSA exposure in a dose-dependent manner. Apoptosis and necrosis were quantified
by FACS after Annexin V-FITC and PI labeling. (a) Representative FACS data for podocytes treated with BSA and AGE-BSA. The abscissa and
ordinate represent the fluorescence intensity of Annexin V-FITC and PI, respectively. (b) Bar graph represents the mean percentages of
apoptosis and necrosis7s.e.m. (n¼ 3). *Po0.05 versus apoptosis of BSA 50mg/ml. #Po0.05 versus necrosis of BSA 50 mg/ml.
Table 1 | Effect of soluble and matrix-bound AGEs on podocyte detachment, anoikis, and apoptosis
BSA 50 lg/ml AGE-BSA 10 lg/ml AGE-BSA 50 lg/ml AGE-BSA 100 lg/ml
Cell number % Of total Cell number % Of total Cell number % Of total Cell number % Of total
Collagen IV coated
Detached 54 90077600 4.270.5 60 20078500 4.370.6 91 80078800 6.570.9 80 30076600 5.770.7
Adherent apoptotic 41 70073700 3.270.3 50 50075200 3.670.7 114 00074300 8.271.4*,# 238 000718 000 16.871.7*
Adherent necrotic 47 40072100 3.670.2 48 40073400 3.570.5 57 00076900 4.170.4 166 000714 000 11.771.2*,D
Total adherent 1 260 00077200 95.870.3 1 360 000797 000 95.770.6 1 300 000764 000 93.570.6 1 350 000771 000 94.370.5
Total 1 310 00071500 1 420 0007100 000 1 390 000756 000 1 430 000765 000
AGE-modified collagen IV coated
Detached 137 00079200 10.470.9f 137 00075200 10.270.4f 157 00076200 12.870.3f 147 00076100 12.370.4f
Adherent apoptotic 65 80072900 5.070.2f 86 30076400 6.570.7f 143 00071300 11.770.9*,#,f 334 000738 000 27.972.6*,D,f
Adherent necrotic 45 40075400 3.470.4 47 60074400 3.670.4 66 60077700 5.470.7 91 700711 000 7.770.9*
Total adherent 1 180 000739 000 89.671.0 1 210 000750 000 89.870.4 1 070 000716 000 87.270.3 1 050 000773 000 87.770.1
Total 1 320 000731 000 1 350 000753 000 1 220 000721 000 1 200 000779 000
AGE, advanced glycation endproduct; BSA, bovine serum albumin;
*Po0.05 versus BSA 50 mg/ml in the corresponding group.
#Po0.05 versus AGE-BSA 10 mg/ml in the corresponding group.
DPo0.05 versus AGE-BSA 50 mg/ml in the corresponding group.
fPo0.05 versus the corresponding group with collagen IV coating.
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activation by AGE-BSA, we examined the nuclear transloca-
tion of FOXO4. As demonstrated by immunofluorescence
staining for FOXO4, AGE-BSA stimulated nuclear transloca-
tion of FOXO4 in podocytes (Figure 9a). We also determined
that the expression of Bim, a downstream effector protein of
apoptosis activated by FOXO,24 was significantly increased by
AGE-BSA exposure in a dose-dependent manner (Figure 9b).
To assess the role of FOXO4 in AGE-induced podocyte
apoptosis, we knocked down the expression of FOXO4 by
more than 75% in podocytes using a FOXO4-specific siRNA
(Figure 10a and b). Inhibition of the FOXO4 expression
diminished AGE-BSA- and CML-BSA-induced podocyte
apoptosis (Figure 10c and d), thus implicating FOXO4 as a
key regulator of podocyte apoptosis due to AGE exposure.
DISCUSSION
This study was designed to investigate the role of the
AGE–RAGE interaction on podocyte apoptosis. We demon-
strated for the first time that murine podocytes in culture
undergo apoptosis when exposed to both soluble AGEs
(CML-BSA and AGE-BSA) and matrix-bound AGEs (AGE-
modified collagen IV). Our data suggest that AGEs play an
important role in reducing the podocyte number via
apoptosis, which could potentially accelerate the develop-
ment and progression of diabetic nephropathy. Our findings
on AGE-induced apoptosis in podocytes are consistent with
previous reports showing AGE-induced apoptosis in osteo-
blasts,25 fibroblasts,20 and neurons.21 Similar to our findings,
increased ROS production was the mechanism that underlies
the apoptosis of fibroblasts and neurons after AGE expo-
sure.20,21
An interesting observation from this study was the
additive effect of soluble AGEs (CML-BSA and AGE-BSA)
and matrix-bound AGEs (AGE-modified collagen IV) on
podocyte apoptosis. Methylglyoxal is an AGE with a reactive
dicarbonyl moiety. Methylglyoxal modification of the argi-
nine-glycine-aspartate motif of collagen IV, the major
extracellular matrix protein in the glomerular basement
membrane, has been shown to cause endothelial cell
detachment and anoikis by interfering with binding of
a1b1 integrin receptor to collagen IV.26 In our study,
targeted-gene knockdown of RAGE did not significantly
reduce the apoptosis of podocytes cultured on AGE-modified
collagen IV. Moreover, we observed a higher percentage of
detachment when podocytes were cultured on AGE-modified
collagen IV versus collagen IV. These findings implied that
mechanisms other than the RAGE–AGE interaction were
responsible for the apoptosis of podocytes cultured on the
AGE-modified substratum; and detachment/anoikis might be
the mechanism of apoptosis triggered by matrix-bound
AGEs. Future studies on the effect of extracellular matrix
modification by AGEs on podocyte attachment and apopto-
sis/anoikis are warranted.
The intracellular pathways activated by oxidative stress
leading to cellular responses are well known. One of these
pathways involves MAP kinases (p38MAPK, extracellular
signal-regulated kinase1/2, JNK). The activation of
p38MAPK has been reported in AGE-induced fibroblast
apoptosis,20 and now in podocyte apoptosis. Akt is a cell
survival factor. We observed that Akt phosphorylation was
suppressed by AGE-BSA. Akt activation by phosphorylation
is an antiapoptotic signal that has been demonstrated
previously in podocytes.27 Growth factors or extracellular
signals lead to the activation of phosphoinositide kinase,
which results in Akt phosphorylation and activation leading
to cell proliferation. In podocytes, both nephrin and CD2AP
are able to stimulate Akt phosphorylation,27 possibly protect
podocytes from programmed cell death and promote
survival. Reduction of nephrin expression has been reported
in human diabetic nephropathy.28 An area of interest for
future studies would be determining if the phosphoinositide
kinase-Akt pathway is defective in podocytes of diabetic
patients and whether overexpression of nephrin can rescue
podocytes from apoptosis.
Forkhead transcription factors (FOXO1, FOXO3, and
FOXO4) are a family of proteins that function as sensors of
signaling pathways and modulate apoptosis, cell cycle, and
metabolism through regulation of gene expression.29 Acti-
vated-Akt phosphorylates and inactivates FOXO proteins.30
In the absence of Akt inhibition, FOXO is translocated to the
nucleus leading to gene activation. FOXO transcription
factors activate three major groups of genes: anti-oxidant
genes, cell cycle arrest genes, and apoptotic genes.22 Our data
suggest that AGEs activate FOXO4 leading to apoptosis in
podocytes. Similarly, Alikhani et al.20 have demonstrated that
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Figure 3 | Targeted gene knockdown of RAGE with siRNA.
Transient transfection of podocytes with a siRNA for RAGE or the
miRIDIAN microRNA Mimic negative control sequence (CL) was
carried out using the Amaxa Nucleofection Device. Transfection
efficiency was measured by the percentage of cells expressing GFP
after transfection with pmaxGFPTM. (a) Representative photographs
of pmaxGFPTM-transfected podocytes under light (top) and
epifluorescence (bottom) microscopy. Effects of siRNA for RAGE and
CL on RAGE mRNA level (b) and protein expression (c) were analyzed
by real-time polymerase chain reaction and Western blotting,
respectively. Representative data from three experiments are shown.
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another FOXO factor, FOXO1, is involved in AGE-induced
apoptosis of fibroblasts. Consistent with prior reports on the
activation of effector proteins of apoptosis (Bim) by
FOXO3a,24 we observed enhanced expression of Bim after
AGE-BSA exposure. The specificity of FOXO transcriptional
activity is influenced by Sirtuin 1 mediated acetylation and
JNK-dependent phosphorylation.31,32 In this study, we did
not examine the expression of Sirtuin 1 with AGE exposure.
Sirtuin 1 is a potential target for pharmacologic modulation
of the FOXO-mediate activation of apoptosis that deserves
further investigation. Stress-activated JNK modulates FOXO
activity by phosphorylation leading to the expression of
apoptosis-related genes.32 In our study, we were unable to
show activation of JNK by AGEs in podocytes. However, AGE
activation of p38MAPK could regulate FOXO transcriptional
activity through a similar pathway, which will need further
studies for confirmation.
In summary, we have shown that AGEs are one of the risk
factors for podocyte depletion in diabetic nephropathy. AGE-
induced podocyte apoptosis is mediated via the activation of
RAGE, ROS production, and FOXO4, providing a novel
mechanism of podocyte injury in diabetic nephropathy. Our
data suggest that FOXO transcriptional activity is an
important determinant of podocyte apoptosis. The role of
FOXO4 in podocytes deserves further investigation in
diabetic animal models. This study provides additional
evidence that the reduction of ROS production, AGE burden,
and RAGE expression are important therapeutic approaches
to slowing the progression of diabetic nephropathy. These
findings may provide us with not only the mechanism of
podocyte injury but also new targets of therapy for diabetic
nephropathy.
MATERIALS AND METHODS
AGE-preparations
Endotoxin-free AGE-BSA was prepared from endotoxin-free,
lyophilized BSA (fraction IV; Sigma, St Louis, MO, USA), and
glucose, as described previously.18 AGE-modified collagen IV and I
were prepared by incubating endotoxin-free, sterile type IV, and I
collagens (BD Bioscience, Bedford, MA, USA) with glucose similar
to the preparation of AGE-BSA. An endotoxin-binding affinity
column (Pierce, Rockford, IL, USA) was used to remove endotoxin
from AGE-BSA, AGE-collagens, and native BSA. The absence of
endotoxin was confirmed by a Limulus amebocyte lysate assay
(BioWhittaker, Walkerville, MD, USA). Endotoxin levels in
preparations were further determined by Associates of Cape Cod
(Falmouth, MA, USA) and were found to be less than 2 endotoxin
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Figure 4 | Knockdown of RAGE in podocytes mitigates the apoptotic effect of AGE-BSA, but not AGE-modified collagen IV.
Apoptosis and necrosis were determined by FACS. Representative FACS data and bar graph summarizing the FACS results are shown.
(a) Summary of FACS for apoptosis and necrosis of podocytes transfected with the siRNA for RAGE and treated with either BSA or AGE-BSA
are shown. *Po0.05 versus BSA 50mg/ml (n¼ 3). (b) Apoptosis of podocytes transfected with the siRNA for RAGE and cultured on
AGE-modified collagen IV. #Po0.05 versus the percentage of apoptosis in the other two groups (n¼ 3).
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units/mg of protein. CML-BSA was a gift from Dr H Vlassara’s
laboratory (Mount Sinai Medical Center, New York, NY, USA).
Cell culture
Conditionally immortalized murine podocytes were obtained from
Dr Peter Mundel (Mount Sinai Medical Center, New York).
Podocytes were cultivated in RPMI 1640 (RPMI) medium contain-
ing 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100mg/ml
streptomycin, and 2 mM L-glutamine. To permit immortalized
growth, the culture medium was supplemented with 10 U/ml of
recombinant mouse g-interferon to induce the expression of T
antigen and cells were cultured at 331C (permissive conditions). To
induce differentiation, cells were cultured on type I or collagen IV at
371C without g-interferon for at least 10 days. We confirmed the
degradation of the T antigen under nonpermissive condition (371C)
by Western blot analysis. Differentiated podocytes were used in the
study. For apoptosis detection by terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labelling (TUNEL) staining,
podocytes were cultured on microscope coverslips.
Determination of podocyte apoptosis, necrosis, and detach-
ment
For all apoptosis detection experiments, differentiated podocytes
were cultured in RPMI medium supplemented with 1% FBS for
overnight along with BSA, AGE-BSA, or CML-BSA at the indicated
concentrations before apoptosis detection. Apoptosis was assessed
by TUNEL staining according to the manufacturer’s protocol
(DeadEnd Colorimetric TUNEL System, Promega, Madison, WI,
USA). Apoptotic cells with nuclei staining dark brown were counted
by light microscopy. The percentage of apoptotic cells was quantified
by counting five different fields at 400 magnification with two in-
dependent investigators. Apoptosis was expressed as the ratio of
apoptotic cells to the total number of cells in the field of view. Fluor-
escence-activated cell sorting (FACS) was used for the quantification
of apoptotic and necrotic podocytes after Annexin V-fluorescein
isothiocyanate (FITC) and propidium iodide (PI) labeling as
described in the manufacturer’s protocol (Annexin V-FITC
Apoptosis Detection Kit I, BD Bioscience, San Jose, CA, USA). All
FACS analyses for apoptosis detection were performed in triplicates.
Equal number of podocytes were cultivated on 6-cm tissue
culture plates coated with either collagen IV or AGE-modified
collagen IV in RPMI medium with 10% FBS for 4–6 h. Cells were
washed with phosphate-buffered saline (PBS), then exposed to
either BSA or AGE-BSA for overnight in RPMI medium with 1%
FBS. Each experimental condition was performed in triplicate. After
overnight treatment, cell culture medium was collected and saved.
Cells were washed once with 1.5 ml of PBS. PBS used for washing
was combined with the saved culture medium. The concentration of
detached cells was determined using a hemocytometer. Adherent
cells remaining on the plate were recovered by incubation with 1
trypsin/ethylenediaminetetraacetic acid solution. Each sample was
counted three times. The percentages of apoptosis and necrosis in
the adherent-cell fraction were determined by FACS after Annexin
V-FITC and PI labeling. The number of apoptotic and necrotic cells
were calculated by multiplying the percentages of apoptosis and
necrosis as determined by FACS to the total number of adherent
cells. The total number of cells was defined as the number of
detached cells plus the number of adherent cells.
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Figure 5 | AGEs isolated from sera of CKD patients induce podocyte apoptosis. The effect of AGEs isolated from sera of patients with stages
3 and 5 CKD-3 and CKD-5 on apoptosis was compared with those of normal subjects (NS). (a) Representative fields of TUNEL at original
magnification 400. (b) Podocytes were transfected with either a negative control oligonucleotide (CL) or the siRNA for RAGE. The mean
percentages of apoptotic cells after exposure to AGEs from groups CKD-3 and CKD-5 are presented in the bar graph. *Po0.01 versus NS. (n¼ 3)
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Isolation of AGE-modified serum proteins using a LZ-linked
Sepharose 4B column
Sera of patients with CKD stages 3 and 5, as defined by Kidney
Disease Outcomes Initiative guidelines, were obtained and pooled
as part of a previous study (J Uribarri, manuscript submitted).
Patients were recruited from the Mount Sinai School of Medicine’s
renal clinic with the approval of the Institutional Review Board
for human investigation. Pool sera from healthy volunteers were
used as the control. AGEs were fractionated from serum with the
use of an LZ-linked matrix column as described by Mitsuhashi
et al.33 The LZ-linked column was prepared by conjugating
LZ, a known AGE-binding protein, to cyanogen bromide-activated
Sepharose 4B beads according to the manufacturer’s instructions.
A control column was prepared by conjugating BSA to Sepharose 4B
beads following the same procedure. One-milliliter samples of
sera were diluted 1:5 with PBS just before loading on LZ columns
(bed volume, 2 ml). After loading the diluted serum samples
and collecting pass-through fractions, LZ columns were exten-
sively washed with PBS. Then the LZ-bound fractions (0.5 ml
per fraction) were eluted with 0.1 N NaOH and neutralized
immediately with HCl. AGE concentration of these aliquots was
determined by enzyme-linked immunosorbent assay, as described
previously.34
Western blotting
Podocytes were lysed with a buffer containing 1% NP40, a protease
inhibitor cocktail and tyrosine and serine-threonine phosphoryla-
tion inhibitors. After determination of protein concentration, cell
lysates were subjected to 8–12% sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis before transfer to polyvinylidine
difluoride membranes. Immunoblottings were performed using
the following specific antibodies from Cell Signaling Laboratory
(Beverly, MA, USA): phospho-Akt (ser308), phospho-p38, phos-
pho-extracellular signal-regulated kinase1/2, phosphatas and tensin
homologue, phospho-FOXO4 (ser193), and total FOXO4. Anti-
bodies against b-actin, Bim, and RAGE were purchased from Sigma,
Chemicon (Temecula, CA, USA), and Affinity BioReagents (Golden,
CO, USA), respectively.
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Figure 6 | ROS production and apoptosis induced by AGE-BSA are diminished by a ROS scavenger, NAC. ROS production was measured
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Inhibition of p38MAPK
For specific inhibition of p38MAPK, podocytes were pretreated with
10 mM of SB203580 (Calbiochem, San Diego, CA, USA) for 2 h in
RPMI medium with 1% FBS before overnight AGE-BSA (50 mg/ml)
stimulation. Experiments were carried out in triplicates.
Quantitative one step real-time polymerase chain reaction
Ribonucleic acid from cultured podocytes was extracted using the
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s protocol. Qiagen OneStep RT-PCR Kit (Qiagen,
Hilden, Germany) was used for quantitative one-step real-time
polymerase chain reaction. The final reaction volume was 20 ml
containing 500 ng of total RNA, 1 QuantiTect SYBR Green
RT-PCR Master Mix, 0.2ml of QuantiTect RT Mix, and 1.0 mM each
of forward (50-AGGAGCGTGCAGAACTGAAT-30) and reverse (50-
TTGGCAAGGTGGGGTTATAC-30) primers for RAGE. The primer
set used for the determination of FOXO4 mRNA level was
purchased from Qiagen (QuantiTect Primers). RNA was reversed
transcribed and directly amplified in the same glass capillary
of a LightCyclerTM system (Roche Diagnostics, Indianapolis, IN,
USA). Cycler condition was reverse transcription for 20 min at 501C,
and then HotStarTaq DNA polymerase activation for 15 min at
951C. This was followed by 45 sequential cycles of denaturation (15 s
of 941C), annealing (30 s of 551C), and extension (30 s at 721C).
Online fluorescence of SYBR Green I was monitored by the
LightCycler for the determination of crossing point. We used the
2DDCp method for the analysis of relative gene expression as
described previously.35
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Figure 7 | AGE-BSA and CML-BSA activate p38MAPK and reduce Akt phosphorylation. (a) A profile of signaling pathway activation in
podocytes after exposure to BSA (50 mg/ml), CML-BSA (50 mg/ml), or AGE-BSA (50 mg/ml) at time 0, 5, 10, 30, 60, and 240 min. (b) Targeted-gene
knockdown of RAGE prevented AGE-BSA-mediated p38MAPK phosphorylation and Akt de-phosphorylation. Representative blots of at least
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Panomics TranSignal DNA/protein arrays
TranSignal transcription factor array profiles multiple transcription
factor–DNA interactions simultaneously. Array profiling was carried
out according to the protocols provided by the manufacturer.
Briefly, nuclear proteins were extracted from cell lysates. The quality
of nuclear proteins was verified using Western blotting for a
cytoplasmic protein, Raf1 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and a nuclear protein, cAMP-responsive element-
binding protein (Cell Signaling Laboratory). Nuclear proteins were
incubated with transcription-factor-specific biotinylated DNA
oligonucleotides. The protein–DNA complexes were purified and
separated from free probes by spin column separation. After
hybridization of the purified oligonucleotides to the array, positive
spots were visualized by enhanced chemiluminescence. This assay
system examines over 350 transcription factors. Experiments were
performed in triplicates. Podocytes were exposed to AGE-BSA
(50mg/ml), CML-BSA (50 mg/ml), or BSA (50 mg/ml) for 2 h in
RPMI medium with 1% FBS.
Determination of ROS production
After treatment with BSA or AGE-BSA for overnight in RPMI
medium with 1% FBS, podocytes were washed twice with warm
RPMI medium. Podocytes were incubated for 45 min at 371C with
10 mmol/l of 20,70-dichlorofluorescein diacetate (Invitrogen) in
RMPI medium. Cells were washed twice with ice-cold PBS, scraped,
and lysed with PBS containing 0.1% Triton-100, and 0.5 mM
ethylenediaminetetraacetic acid. Luminescence spectrometer Perkin-
Elmer LS50B (Perkin-Elmer, Wellesley, MA, USA) was used for the
measurement of emitted fluorescence at 530 nm with the excitation
wavelength of 485 nm.
Inhibition of ROS production with NAC
NAC (Sigma) is a free radical scavenger. Differentiated podocytes
were pretreated with 2 mM of NAC for 2 h, then incubated with
AGE-BSA (50 mg/ml) in 1% FBS for overnight before labeling with
Annexin IV-FITC and PI.
Immunofluorescence of FOXO4 in podocytes
Podocytes cultured on coverslips were exposed to either BSA or
AGE-BSA at 50 mg/ml in RPMI with 1% FBS for 2 h and then fixed
in 4% paraformaldehyde at room temperature for 15 min. After
permeabilization in 1% Triton, cells were incubated with anti-
FOXO4 polyclonal antibody (Cell Signaling Laboratory) at room
temperature for 1 h. After washing, cells were incubated with
fluorescence-labeled secondary antibodies from Invitrogen (Alexa
Fluor 488 anti-rabbit immunoglobulin G or Alexa Fluor 568 anti-
rabbit immunoglobulin G). Hoechst 33258 dye (Invitrogen) was
used for nuclear staining. After mounting, slides were examined
using a fluorescent microscope.
Target gene knockdown using gene-specific siRNAs
Podocytes were transiently transfected using the Amaxa Nucleofection
technology (Amaxa Biosystems, Gaithersburg, MD, USA), which
utilizes electroporation for gene transfer. We tested several protocols
based on the manufacturer’s instructions. After optimization, we were
able to achieve 80–90% transfection efficiency based on GFP
expression using Amaxa’s Nucleofection kit and Program T-20
(Figure 3a). Transfection efficiency was determined by co-transfection
of podocytes with a vector (pmaxGFPTM) encoding the GFP and
counting the percentage of GFP-positive cells. We used a technique
combining the Dharmacon On TargetPlus SMARTpool siRNAs and
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Figure 9 | AGE-BSA stimulates nuclear translocation of FOXO4 and increases Bim expression. Podocytes were treated with AGE-BSA
(50mg/ml), CML-BSA (50 mg/ml), and BSA (50mg/ml) for 2 h in RPMI medium with 1% FBS. (a) Representative photographs of
immunofluorescence staining for FOXO4 and nuclear staining with Hoechst 33258 dye at original magnification 400. (b) A representative
Western blot for Bim expression after AGE-BSA or BSA incubation.
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Amaxa RNAi Nucleofection kit to successfully introduce siRNAs into
podocytes. Two million podocytes grown to 70–80% confluence and
1.5mg of Dharmacon On Target Plus SMARTpool siRNA were used
for each Nucleofection reaction. Cell survival after transfection was
about 50–60%. Transfected podocytes were cultivated for at least 72 h
in RPMI medium with 10% FBS before treatment with BSA, AGE-
BSA, or CML-BSA in RPMI medium with 1% FBS. miRIDIAN
microRNA Mimic Negative Control (CL) sequence based on C.
elegans miRNA from Dharmacon Corporation (Lafayette, CO, USA)
was used as negative experimental controls in mammalian cells (50-
UCACAACCUCCUAGAAAGAGUAGA-30). The specific siRNAs tar-
geting FOXO4 and RAGE were purchased from Dharmacon
Corporation (Dharmacon On Target Plus SMARTpool siRNAs).
Statistical analysis
The data were presented as mean7s.e.m. For Western blot analyses,
all experiments were repeated at least three times. Statistically
significant differences between the means were determined by the
unpaired t-test or the Mann–Whitney U-test where appropriate.
Significance was defined as a Po0.05.
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